Stephens Inc. AR acquired a new stake in shares of Glaukos Corporation (NYSE:GKOS – Free Report) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 3,371 shares of the medical instruments supplier’s stock, valued at approximately $363,000.
Several other hedge funds and other institutional investors also recently made changes to their positions in the company. First Horizon Corp increased its position in shares of Glaukos by 1,715.4% in the fourth quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier’s stock worth $27,000 after acquiring an additional 223 shares in the last quarter. Los Angeles Capital Management LLC purchased a new stake in shares of Glaukos in the 4th quarter valued at approximately $28,000. Larson Financial Group LLC lifted its position in shares of Glaukos by 62.0% in the 4th quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock valued at $39,000 after acquiring an additional 132 shares in the last quarter. Farther Finance Advisors LLC boosted its stake in Glaukos by 111.4% in the 4th quarter. Farther Finance Advisors LLC now owns 408 shares of the medical instruments supplier’s stock worth $46,000 after purchasing an additional 215 shares during the period. Finally, Salomon & Ludwin LLC boosted its stake in Glaukos by 111.2% in the 4th quarter. Salomon & Ludwin LLC now owns 454 shares of the medical instruments supplier’s stock worth $51,000 after purchasing an additional 239 shares during the period. 99.04% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling at Glaukos
In other news, CFO Alex R. Thurman sold 10,000 shares of the firm’s stock in a transaction on Monday, July 6th. The shares were sold at an average price of $150.00, for a total transaction of $1,500,000.00. Following the transaction, the chief financial officer owned 43,681 shares in the company, valued at approximately $6,552,150. This trade represents a 18.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gilbert H. Kliman sold 5,000 shares of Glaukos stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $140.76, for a total transaction of $703,800.00. Following the completion of the sale, the director directly owned 35,528 shares of the company’s stock, valued at approximately $5,000,921.28. The trade was a 12.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 51,273 shares of company stock valued at $7,332,003. 5.90% of the stock is currently owned by insiders.
Glaukos Stock Up 0.0%
Glaukos (NYSE:GKOS – Get Free Report) last released its quarterly earnings data on Wednesday, April 29th. The medical instruments supplier reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.12. The firm had revenue of $150.57 million for the quarter, compared to the consensus estimate of $137.00 million. Glaukos had a negative return on equity of 6.92% and a negative net margin of 34.34%.The firm’s revenue was up 41.2% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.22) earnings per share. On average, equities research analysts expect that Glaukos Corporation will post -0.57 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several equities analysts have weighed in on GKOS shares. HC Wainwright began coverage on shares of Glaukos in a research report on Monday, July 6th. They set a “buy” rating and a $168.00 price objective on the stock. Wells Fargo & Company raised their target price on Glaukos from $135.00 to $138.00 and gave the stock an “overweight” rating in a research report on Thursday, April 30th. BTIG Research reiterated a “buy” rating and set a $162.00 price target on shares of Glaukos in a report on Wednesday, June 10th. Wall Street Zen upgraded Glaukos from a “hold” rating to a “buy” rating in a report on Saturday, July 4th. Finally, Needham & Company LLC upped their price target on Glaukos from $136.00 to $150.00 and gave the company a “buy” rating in a research report on Wednesday, June 17th. Thirteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $151.62.
View Our Latest Stock Report on GKOS
About Glaukos
Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.
Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.
Featured Articles
- Five stocks we like better than Glaukos
- 3 Rare-Earth ETFs That Help Investors Balance Exposure and Risk
- Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs
- Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing
- This Dividend ETF Choice Could Shape Your Income Strategy Through 2026
Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corporation (NYSE:GKOS – Free Report).
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.
